Article
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Nature - 1 Aug 2023
Isozaki Hideko, Sakhtemani Ramin, Abbasi Ammal, Nikpour Naveed, Stanzione Marcello, Oh Sunwoo, Langenbucher Adam, Monroe Susanna, Su Wenjia, Cabanos Heidie Frisco, Siddiqui Faria M, Phan Nicole, Jalili Pégah, Timonina Daria, Bilton Samantha, Gomez-Caraballo Maria, Archibald Hannah L, Nangia Varuna, Dionne Kristin, Riley Amanda, Lawlor Matthew, Banwait Mandeep Kaur, Cobb Rosemary G, Zou Lee, Dyson Nicholas J, Ott Christopher J, Benes Cyril, Getz Gad, Chan Chang S, Shaw Alice T, Gainor Justin F, Lin Jessica J, Sequist Lecia V, Piotrowska Zofia, Yeap Beow Y, Engelman Jeffrey A, Lee Jake June-Koo, Maruvka Yosef E, Buisson Rémi, Lawrence Michael S, Hata Aaron N
Abstract excerpt
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified1-4, the underlying molecular mechanisms shaping tumour evolution during treatment are incompletely understood. Genomic profiling of patient tumours has implicated apolipoprotein B messenger RNA editing catalytic polypeptide-like (APOBEC) cytidine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.